Comparison

c-Kit-IN-3 (hydrochloride)

Item no. CS-0107041-10mg
Manufacturer ChemScene
Amount 10mg
Category
Type Molecules
Specific against other
ECLASS 10.1 32169090
ECLASS 11.0 32169090
UNSPSC 12000000
Available
Purity
>98%
MWt
553.36
Formula
C26H21Cl2F3N2O4
Solubility
10 mM in DMSO
Clinical Information
No Development Reported
Pathway
Protein Tyrosine Kinase/RTK
Target
c-Kit
Biological Activity
c-Kit-IN-3 hydrochloride (Compound 18) is a potent c-KIT kinase inhibitor, which is potent and selective against BaF3-tel-c-KIT (IC50 of 4 nM) and a broad spectrum of drug-resistant mutants (IC50 of 8 nM for BaF3-tel-c-KIT-T670I) with improved bioavailability[1]. IC50 & Target: IC50: 4 nM (BaF3-tel-c-KIT); 8 nM (BaF3-tel-c-KIT-T670I)[1] In Vitro: c-Kit-IN-3 hydrochloride (Compound 18; 0.006 uM-1.37 uM) potently inhibits the growth of c-KIT-dependent GIST cancer cells, such as GIST-T1 (IC50: 0.006 uM); GIST-882 (IC50: 0.013 uM); GIST-T1-T670I (IC50 : 0.011 uM); GIST-5R (IC50: 0.073 uM); GIST-48B (IC50: 1.37 uM), respectively[1].
c-Kit-IN-3 hydrochloride(Compound 18; 0.01-1 uM; 24 hours; GIST-T1, GIST-T1-T670I, and GIST-5R cells) treatment induces dose-dependent cell apoptotic death (by examining the cleaved PARP and cleaved caspase 3)[1].
c-Kit-IN-3 hydrochloride (Compound 18; 0.01-1 uM; 24 hours; GIST-T1, GIST-T1-T670I, and GIST-5R cells) treatment arrests the cell cycle into the G0/G1 phase in all of these three cell lines[1].
c-Kit-IN-3 hydrochloride (Compound 18; 0.1-10 uM; 6 days; primary GIST patient cells) exhibits dose-dependent antiproliferative effects[1].
c-Kit-IN-3 hydrochloride (Compound 18; 0-1 uM; 24 hours) blocks the autophosphorylation of c-KIT pY703, pY719, and pY823 in GIST-T1, GIST-T1-T670I, and GIST-5R, respectively, cells at a concentration of 30 nM and inhibits the downstream signaling mediators pAKT (T308/S473), pS6 (S235/236), and pERK (T202/204)[1].
c-Kit-IN-3 hydrochloride (Compound 18; 0-1 uM; 2 hours) induces dose-dependent cell apoptotic death (by examining the cleaved PARP and cleaved caspase 3) and arrest the cell cycle into the G0/G1 phase in all of these three cell lines[1].
In Vivo: c-Kit-IN-3 hydrochloride (Compound 18; 40-100 mg/kg; oral gavage; daily; for 11 days; for 4 weeks; female BALB/C-nu mice) treatment dose dependently inhibits the BaF3-tel-c-KIT-T670I tumor progression and exhibited almost 100% TGI (tumor growth inhibition) at a dosage of 100 mg/kg/day. And do not affect the animal weights[1].
Research Area
Cancer

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 10mg
Available: In stock
available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close